Latest Breaking News On - Radiohybrid prostate specific membrane antigen - Page 5 : comparemela.com

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent ¹⁸F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent ¹⁸F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesClare gidleyDavide gaudenBriant helfandPriscilla harlanMike beyerScintomics gmbBracco groupSam brown incDivision of urologyTechnical university of munichNuclear medicineNorthshore university healthsystemDrug administrationCorporate communications

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesScintomics gmbBriant helfandDavide gaudenDivision of urologyBracco groupDrug administrationNorthshore university healthsystemTechnical university of munichAmerican urological associationNuclear medicineStudy groupEarth diagnosticsDetection ratesProstate specific antigenProstate specific membrane antigen targeted

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

- Results to be presented at American Urological Association's 2023 Annual Meeting (AUA2023) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization

Mccormick placeUnited statesUnited kingdomPriscilla harlanScintomics gmbBriant helfandMike beyerClare gidleyNorthshore university healthsystemBracco groupAmerican urological associationNuclear medicineStudy groupCorporate communicationsCompany at boothDivision of urology

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

Results of the Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer to be presented at 2023 ASCO Genitourinary Cancers Symposium (ASCO GU)

United statesSan franciscoScintomics gmbBrianf chapinUniversity of texas md anderson cancer centerStudy groupDivision of surgeryTechnical university of munichDuke university medical centerDepartment of urologyBlue earth diagnostic medical affairsBlue earth diagnosticsCancers symposiumProstate specific membrane antigen targetedEmission tomographyAdvanced prostate cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Newly Diagnosed Prostate Cancer

First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)

San diegoUnited statesScintomics gmbDavide gaudenBrianf chapinTechnical university of munichDivision of surgeryUniversity of texas md anderson cancer centerDepartment of urologyDrug administrationStudy groupBlue earth diagnosticsProstate specific membrane antigen targetedAnnual scientific meetingUrologic oncologyAssociate professor